The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

FREE Educational Webinar: What You Need to Know About HCV

Back to News Homepage

Next

Diet Supplement Tied to Hepatitis

New Hepatitis C Study Cures 90% of Patients

Print this page

Learn more about the combination of two anti-viral drugs (daclatasvir and asunaprevir) developed by Bristol-Myers Squibb Co that has been highly effective and well tolerated among study participants.

Bristol-Myers hepatitis C treatment cures up to 90 percent in new study

Reuters

A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.

The Phase III trial of more than 700 patients called Hallmark-Dual tested a combination of Bristol’s daclatasvir and asunaprevir over 24 weeks of therapy in patients with genotype 1b of the virus that causes progressive liver disease.

Continue reading this entire article:
http://www.foxnews.com/health/2014/04/10/bristol-myers-hepatitis-c-treatment-cures-up-to-0-percent-in-new-study/

19 Comments
Share
Share

Previous

FREE Educational Webinar: What You Need to Know About HCV

Back to News Homepage

Next

Diet Supplement Tied to Hepatitis

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.